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Developing alternative over-the-counter medicine label formats: how do 1 
they compare when evaluated by consumers? 2 
Abstract 3 
 4 
Background 5 
In recent years, the Australian Therapeutic Goods Administration (TGA) has proposed 6 
implementing a standardized over-the-counter (OTC) medicine label. However, there 7 
were mixed consumer opinions regarding a label proposed in 2012 and limited 8 
evidence demonstrating the usability of the revised (2014) format.  9 
Objective 10 
To develop and examine the usability of alternative OTC medicine label formats for 11 
standardization, and explore consumer perspectives on the labels. 12 
Materials and methods  13 
Four alternative labels were developed for the exemplar medicine diclofenac. One was 14 
based on the Medicine Information label proposed by the TGA (‘Medicine 15 
Information’), one was based on the U.S. Drug Facts label (‘Drug Facts’), and two were 16 
based on suggestions proposed by consumers in the earlier needs analysis phase of 17 
this research (referred to as the ‘Medicine Facts’ and ‘Consumer Desires’ label 18 
formats). Five cohorts of 10 participants were recruited. Each cohort was assigned to 19 
user test one of the alternative labels or an existing label for a proprietary diclofenac 20 
product (which acted as a comparator) for diagnostic purposes. Each participant then 21 
provided feedback on all 5 labels. Each interview consisted of the administration of a 22 
user testing questionnaire, measuring consumers’ ability to find and understand key 23 
points of information, and a semi-structured interview exploring consumer 24 
perspectives. 25 
  26 
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Results  27 
Overall, all 4 alternative label formats supported consumers’ ability to find and 28 
understand key points. The existing comparator label was the poorer label with 29 
respect to participants’ ability to find and understand key points. Factors such as 30 
perceived usability, color, design, content, and/or content ordering impacted 31 
consumer preferences. The ‘Consumer Desires’ or ‘Drug Facts’ label formats were 32 
most often preferred by consumers for use as the standardized OTC label over the TGA 33 
proposed format.  34 
Conclusions 35 
All alternative label formats demonstrated satisfactory usability and could be 36 
considered for use in OTC label standardization. User testing of OTC labels and 37 
consumer feedback received as part of the testing process can assist in the refinement 38 
of OTC labeling to ensure that implemented policies are evidence-based. 39 
 40 
Keywords 41 
 42 
Drug labeling; user testing; nonprescription medicines; comprehension; consumers. 43 
 44 
  45 
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Introduction 46 
 47 
Availability and access to over-the-counter (OTC) medicines is essential to support 48 
consumers in their autonomy and choice to self-manage minor ailments. Appropriate, 49 
user-friendly information must therefore accompany OTC medicines to facilitate this, 50 
notably the information included on OTC medicine packaging. This information, 51 
hereafter referred to as the OTC label or OTC labeling, encompasses both the medicine 52 
information included on the packaging and how it is presented i.e. the label’s design.  53 
A complex interplay of factors is involved in balancing the design and content included 54 
on an OTC label to yield a written medicine information source that is fit-for-purpose.
1
 55 
Various strategies help to safeguard and/or improve OTC labeling quality, such as 56 
legislation and guidelines.
2, 3 
Application of guidelines such as good information design
4
 57 
result in improved OTC labeling.
1
 However, label design may not always adhere to 58 
guidelines,
5, 6 
and deficiencies may lead to suboptimal comprehension of OTC medicine 59 
information.
1
 An example of a more specific strategy to optimize medicine labeling is 60 
the standardization of OTC labels in the United States (U.S.) using the Drug Facts label 61 
format.
7
 Testing demonstrated a number of positive benefits associated with this 62 
standardized format
8
 such as improvement in the time to locate information.
9, 10
  63 
In recent years, OTC label standardization as a strategy has also been proposed for 64 
implementation in different regulatory contexts such as Australia
11, 12
 and Canada.
13
 65 
The rationale for OTC label standardization, as proposed by the relevant Australian and 66 
Canadian regulatory authorities, was underpinned by the aim of promoting safer and 67 
more effective use of OTC medicines by consumers.
11, 13
 If information was presented 68 
consistently, it was postulated that it would support appropriate self-selection of OTC 69 
medicines and that consumers could more easily locate information on OTC labels 70 
across different products.
11, 13
  71 
Within the Australian context, as part of a general public consultation in 2012, the 72 
Australian Therapeutic Goods Administration (TGA) sought feedback on a proposal put 73 
forward for standardized OTC labeling in Australia.
11
 However, there was a lack of 74 
published data detailing consultations with consumers that helped to inform the 75 
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details of this proposal. Consequently, in response to the initial 2012 consultation, 76 
semi-structured interviews were conducted with 38 Australian and 39 UK consumers 77 
to explore consumer opinions on OTC label standardization and the Medicine 78 
Information Box format (MIB) (which was the proposed standardized OTC label 79 
format
11
 presented in the 2012 Australian TGA consultation paper).
14
 Additional focus 80 
group discussions complemented the interviews and explored consumer perspectives 81 
on current non-standardized Australian OTC labels, and the U.S. Drug Facts label (on 82 
which the MIB is based
11
), in comparison to the MIB.
15
 It was found that in general, 83 
consumers felt positively towards OTC label standardization, which was regarded as a 84 
strategy that could help promote ease and familiarity in retrieving information from a 85 
label.
14
 However, mixed consumer opinions on the MIB format were highlighted and a 86 
plethora of suggestions for improvement were also proposed.
14, 15
 Moreover, 87 
consumers also indicated a preference for the Drug Facts label format over the MIB.
15
 88 
Consequently, this emphasized the need to explore ways to redevelop and optimize 89 
the MIB format prior to its integration into updated OTC labeling policies.   90 
Proceeding the 2012 consultation, a further public consultation on an updated 91 
proposal was conducted in 2014
12
 along with a targeted consultation in 2015.
16
 92 
Despite this, a paucity of evidence exists in the published literature supporting the 93 
usability of the specific TGA OTC standardized label formats proposed in both 2012 and 94 
2014 for implementation within an Australian context. Additionally, there is a lack of 95 
data comparing its usability with other label formats that have been developed using 96 
feedback directly obtained from consumers. Unlike how the U.S. Food and Drug 97 
Administration tested their proposed Drug Facts label with consumers,
7
 the superior 98 
usability of the TGA proposed standardized format, and thus, further reassurance that 99 
the labeling policy is evidence-based from a label usability perspective, has not been 100 
clearly demonstrated in the published literature. Therefore, this study aimed to:  101 
1. Develop and test alternative standardized OTC medicine label formats, 102 
informed by consumer opinions and good information design;  103 
2. Compare the usability of the developed OTC label formats to an existing 104 
Australian OTC label for the exemplar medicine diclofenac; and 105 
3. Explore consumer perspectives on all study labels. 106 
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Materials and methods 107 
 108 
The present study forms part of a broader international collaborative project on OTC 109 
labeling improvement and standardization. Research ethics approval for the conduct of 110 
this study was obtained from the Human Research Ethics Committee of Institution 1. 111 
Participants provided written informed consent prior to participation. All participants 112 
were reimbursed for their time. 113 
The present study comprised two stages:  114 
1. Development of alternative standardized OTC label formats, and 115 
2. User testing of the label formats with consumers. 116 
 117 
Development of alternative standardized OTC label formats 118 
Within the broader international project, a qualitative needs analysis (semi-structured 119 
interviews
14
 and focus groups
15
) was conducted with consumers to explore their 120 
opinions on existing and proposed OTC labeling strategies to help inform OTC label 121 
optimization. Label development commenced after the needs analysis had been 122 
completed. The needs analysis findings were evaluated by an international panel and 123 
consensus was reached by the research team on the specific suggestions to be taken 124 
forward. Broad reasons why certain suggestions were not taken forward included:  125 
• The suggestions were outside the scope of the study e.g. use of Braille on the 126 
packaging, pictographs; 127 
• The suggestions were too content-specific and/or could negatively impact the 128 
safe use of the medicine e.g. deletion of important information relevant to 129 
when the product is being used; and/or 130 
• The suggestions were only proposed by a very small number of consumers. 131 
The needs analysis findings were used in consultation with a UK information design 132 
expert, together with reference to good information design principles
4
 and use of plain 133 
English, to inform the development of alternative OTC label formats for the exemplar 134 
medicine diclofenac that could be considered for implementation as part of a label 135 
standardization policy (Table 1, Figures 1-4).  136 
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Table 1. Developed alternative standardized OTC label formats for exemplar medicine 137 
diclofenac 138 
 Label  Brief description 
 
 
 
Existing or 
proposed 
standardized 
label formats 
‘Medicine 
Information’ 
(Figure 1)  
This label was based on the design outlined in the 
Australian TGA consultation paper released in August 
2014,
12
 which appeared to integrate the findings from 
the initial consultation
11
 (replacing the Medicine 
Information Box (MIB) label proposed in 2012). 
• Black print on white background 
‘Drug Facts’ 
(Figure 2)  
This label was based on the Drug Facts standardized OTC 
label format implemented in the U.S.
7
 Many focus group 
participants
15
 preferred this format. 
• Black print on white background 
• Information split across 2 panels (of the box) 
 
 
 
 
 
 
Novel label 
formats 
developed 
‘Medicine 
Facts’  
(Figure 3) 
‘Medicine Facts’ was a consumer-proposed label title.
15
 
The needs analysis findings were applied in the 
development of this format.
14, 15
 Aspects of previously 
implemented and tested written medicine information 
formats such as the U.S. Drug Facts label
7
 and Australian 
Consumer Medicine Information
17
 formats were also 
integrated. 
• Navy blue print on white background 
• Information split across 2 panels (of the box) 
‘Consumer 
Desires’ 
(Figure 4) 
Findings from the needs analysis were applied to inform 
the development of this format.
14, 15
 Some specific 
consumer desires
14
 were integrated into this format as 
they were seen to have merit, but which were not 
reported by a large proportion of consumers. 
• Navy blue print on light blue background 
• Warnings section presented in red 
• Simple pictograph system highlighting indications and 
contraindications using ticks and crosses, respectively 
 139 
A total of 4 designs were developed and finalized via consensus amongst all research 140 
team members for the exemplar study medicine diclofenac (Table 1, Figures 1-4). The 141 
MIB format developed for earlier research
14, 15
 for diclofenac (one of the exemplar 142 
medicines utilized in previous studies) was adopted as the baseline label and additional 143 
label content, where necessary, was derived and/or adapted from the information 144 
available for an existing diclofenac product (Voltaren® Rapid 25 tablets).
18, 19
  145 
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Each label was incorporated and presented as part of complete OTC packaging for the 146 
fictitious brand “Viffarol” for evaluation (Figure 5 provides an example of the complete 147 
OTC packaging). The complete OTC packaging size was uniform for all Viffarol labels; 148 
when assembled, the packaging dimensions were: 115 mm (l) x 48 mm (w) x 24 mm (h). 149 
An existing label for an Australian diclofenac proprietary product (Voltaren® Rapid 25 150 
tablets
18
; dimensions: 105 mm (l) x 45 mm (w) x 20 mm (h)) was also chosen as a 151 
comparator label format for user testing to help evaluate the relative usability of the 152 
OTC label formats. No changes were made to the existing Voltaren® Rapid 25 label. 153 
 154 
User testing of the label formats with consumers 155 
Once all alternative label formats were developed, user testing of the label formats 156 
was then undertaken with consumers. User testing
17
 is a method of testing conducted 157 
with members of the public that is used as the standard in Europe to test patient 158 
information leaflets. It has also been advocated for use in OTC label development,
2
 159 
used in usability testing and improvement of written medicine information.
17, 20, 21
 User 160 
testing was conducted with demographically matched cohorts of consumers as a 161 
diagnostic measure of the usability of the developed label formats. Both quantitative 162 
and qualitative data were obtained using a standardized user testing questionnaire 163 
(UTQ) developed specifically for the exemplar medicine diclofenac. Explicit user testing 164 
outcome measures used to ascertain the usability of the written medicine information 165 
included the ability to find and understand the information. Thus, each study 166 
participant only user tested 1 of the 5 labels to ensure that the validity of both key 167 
outcome measures was not compromised due to factors such as recall of information 168 
relevant to diclofenac. 169 
 170 
Development of the user testing questionnaire and semi-structured interview protocol 171 
A UTQ was developed, consisting of 13 core items that encompassed key points of 172 
information specific to the diclofenac product as agreed upon by 3 pharmacists 173 
(Authors 1-3). Some UTQ items were derived from the UTQ used in an earlier study 174 
(within the broader international collaborative project) that evaluated a label and 175 
leaflet for diclofenac (manuscript prepared for publication).  176 
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Questionnaire items were asked in an order which minimized key points corresponding 177 
to the exact order they appeared in the information across the label formats (so that 178 
respondents did not learn that the relevant information to answer a question was 179 
positioned immediately after that for the previous question). The standardized order 180 
of questions was also intended to minimize any order effects within and between 181 
cohorts. 182 
A semi-structured interview protocol was also developed for use after the UTQ to 183 
explore consumer perspectives on the label formats (Appendix 1). Both the UTQ and 184 
semi-structured interview protocol were piloted with 2 non-medically trained people 185 
and 2 pharmacists engaged in research for face and content validity, which involved 186 
detailed individual review of all questions. Approximately 2 weeks afterwards, each 187 
person completed the entire face-to-face session as a mock participant (with the 188 
interviewer) to determine whether any further improvements to the interview process 189 
were required. Minor amendments to the wording of items included in both the UTQ 190 
and interview protocol were subsequently made to improve item clarity.  191 
 192 
User testing- participants and setting 193 
Study recruitment was conducted between April and October 2015 using online 194 
advertisements, recruitment flyer distribution, and by a market research company.  195 
Consumers were eligible to participate in the study if they were:  196 
• 18 years or older, 197 
• Conversant in English (did not require the assistance of a translator to complete 198 
the interview tasks), 199 
• Had purchased and used an OTC medicine (for themselves or had given it to a 200 
person under their care) within the 6 months prior to study participation,  201 
• Had not used diclofenac (either for themselves or given to a person under their 202 
care) within the 6 months prior to study participation, and 203 
• Had not used or given someone under their care a medicine from the same 204 
therapeutic class as diclofenac (non-steroidal anti-inflammatory drugs (NSAIDs) 205 
for pain relief) within 1 month prior to study participation. 206 
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Participants were excluded if they: 207 
• Were a retired or practicing health care professional, 208 
• Were currently employed in an occupation which primarily involved the use of 209 
medicine information, 210 
• Had participated in a user testing study in the 6 months prior to study 211 
participation, or 212 
• Had significant visual or cognitive impairment that could affect study 213 
participation. 214 
In accordance with user testing guidelines in place in the European Union for written 215 
medicine information, satisfactory usability is achieved when a minimum of 8 out of 10 216 
participants in a cohort are able to demonstrate their ability to both find and 217 
understand each key point of information.
20
 As user testing was used diagnostically, 218 
only 10 participants per label format were required for one round of testing; where 219 
applicable, additional testing can be undertaken to evaluate necessary label revisions 220 
made as a result of any identified issues.
21
 Therefore, each cohort (that consisted of 10 221 
participants) user tested a different assigned OTC label format for diagnostic purposes 222 
and each participant then provided feedback on all 5 labels. Five cohorts of 10 223 
participants were recruited. Each cohort was demographically matched using criteria 224 
that were adapted from a previous study.
22
 These criteria acted as controlled variables 225 
per cohort to ensure an adequate spread of participant demographics and allowed for 226 
a degree of comparison between cohorts. 227 
Each cohort was demographically matched by gender (at least 3 males and 3 females 228 
per cohort of 10), education (a maximum of 3 participants per cohort of 10 having 229 
completed a university degree or higher), occupation/use of written information (at 230 
least 2 participants per cohort of 10 unemployed or retired, or did not regularly use 231 
written information as part of their occupation), and age (at least 1 participant per 232 
cohort of 10 representing each of the following adult age brackets: 18-29, 30-39, 40-233 
49, 50-59, 60-69, and 70+ years). Once recruited, participants were assigned a specific 234 
label to user test in order to ensure that all demographic requirements were met per 235 
cohort.  236 
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Study protocol 237 
Data were collected via individual face-to-face interviews, lasting approximately 1 hour 238 
in total (at Institution 1). All interviews were conducted by 1 researcher (Author 1) to 239 
ensure consistency in their conduct and were audio-recorded with permission from 240 
the participants.  241 
Each face-to-face interview consisted of 2 parts:  242 
(i) Administration of the UTQ to test 1 assigned label format, and 243 
(ii) A semi-structured interview component exploring consumer opinions on all 244 
label formats.  245 
At the interviews, participants were given a copy of the participant information 246 
statement and consent form to read and sign. The assigned label for testing was 247 
provided to the participant and they were given as much reading time as required. The 248 
structured UTQ was then administered. Participants kept the label in front of them at 249 
all times. Participants were then asked for their feedback on the label they had user 250 
tested regarding aspects such as the design, content, and wording. All other labels 251 
were then presented together and participants were asked for their opinions on the 252 
different label formats. All labels could be viewed side by side by the participants. They 253 
were also requested to rank all the label formats from the most to least preferred and 254 
explain their reasoning. Finally, they were asked to select a label format they would 255 
choose to implement as a standardized OTC label format.  256 
 257 
  258 
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Data analysis 259 
User testing data analysis 260 
All audio recordings were reviewed after interview completion and participant 261 
responses to the UTQ were transcribed verbatim for analysis. Responses were coded 262 
according to the model answers for the UTQ items as:  263 
• Found and understood; 264 
• Found but not understood, or; 265 
• Not found (understanding was therefore not applicable). 266 
To help provide an indication of the ease in locating the key point of information, in 267 
the instances where information was found, answers were noted to be found with 268 
difficulty if the participant:  269 
• Took more than 2 minutes to locate the complete indicative answer on the 270 
label, or;  271 
• Two or more prompts were required to be initiated by the interviewer (Author 272 
1) prior to the indicative answer being located in full on the label. 273 
The above criteria for noting answers as ‘found with difficulty’ were adapted from a 274 
previous user testing study.
22
  275 
All coding was completed by 1 researcher (Author 1). Coding for finding and 276 
understanding information was dichotomous. Therefore, regardless of whether an 277 
answer was found with difficulty, if the relevant information was located by the 278 
participant, it was still coded as found. Similarly, responses were coded as understood 279 
if an answer was provided that corresponded to the complete indicative answer to the 280 
questionnaire item that was agreed upon by the research team members. All answers 281 
that were not clearly found and understood as per the model answers were reviewed 282 
by another researcher (Author 3) and reconciled where necessary to ensure that 283 
agreement was reached in their coding. 284 
 285 
  286 
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Semi-structured interview data analysis 287 
The qualitative semi-structured interviews were transcribed verbatim. Each transcript 288 
was then checked against the audio recording to ensure accuracy. Checked verbatim 289 
transcripts were thematically analyzed.
23
 Matrix displays
24
 were developed and used in 290 
preliminary data analysis to display the semi-structured interview data under broad 291 
themes. Themes and subthemes were then derived inductively from the data and 292 
refined. 293 
Participant label rankings were pooled for analysis and represented numerically. A 294 
standard competition (“1224”) ranking approach
25
 was utilized to take into account 295 
equal label rankings nominated by some participants, where points were assigned to 296 
correspond with each rank. Five points was awarded to the label ranked 1
st
 (most 297 
preferred) and the allocated points were decreased by 1 point with each subsequent 298 
rank to the minimum of 1 point awarded for the label ranked 5
th
 (least preferred). 299 
These were then tallied.  300 
  301 
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Results 302 
 303 
A total of 50 participants (Table 2) completed the study (10 participants per label 304 
format).  305 
 306 
User testing results 307 
User testing results for the 4 alternative OTC label formats 308 
Overall, the label formats generally well supported consumers’ ability to both find and 309 
understand the majority of key points of information for diclofenac (Table 3).  310 
UTQ item 8 relating to sucrose proved problematic for 2 participants in each relevant 311 
cohort when the ‘Medicine Facts’ and ‘Consumer Desires’ label formats were user 312 
tested (Table 3). Sucrose was unable to be located on the label by those participants. 313 
In response to UTQ item 10, related to persistent pain and the actions to be taken, 314 
between 2 and 5 participants in each cohort had difficulty in finding the key 315 
information; in particular, participants had difficulty understanding the maximum 316 
treatment duration before needing to contact their doctor (Table 3).  317 
 318 
User testing results for the Voltaren® Rapid 25 comparator label 319 
Despite participants’ ability to locate the majority of key points of information when 320 
user testing the comparator label Voltaren® Rapid 25, it was the label format that 321 
demonstrated poorer usability relative to the other labels. Specific problem areas were 322 
the understanding of dosage, warning about use in pregnancy, and actions to be taken 323 
in relation to UTQ item 10 (Table 3). Maximum treatment duration could not be found 324 
by 1 participant.  325 
 326 
  327 
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Feedback obtained on the user tested label format 328 
Suggestions put forward by participants were categorised as design, content, or 329 
wording improvements. Common broad improvements suggested for the label formats 330 
included:  331 
• More bolding of key terms or points of information, 332 
• Increased font size, and 333 
• Further use of color, in particular for highlighting or differentiation of 334 
information e.g. warnings information to be highlighted using the color red. 335 
Other more label-specific suggestions for improvement have been summarized in 336 
Table 4.   337 
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Table 2. Summary of participant demographics 338 
Demographic  Voltaren
®
  
Rapid 25  
cohort  
(n=10) 
‘Medicine 
Information’ 
cohort  
(n=10) 
‘Medicine 
Facts’ 
cohort 
(n=10) 
‘Consumer 
Desires’ 
cohort 
(n=10) 
‘Drug 
Facts’ 
cohort 
(n=10) 
Total 
(n=50) 
Gender Male 4 5 5 5 5 24 
Female 6 5 5 5 5 26 
Age, years 18-29 3 3 3 3 3 15 
30-49 3 3 2 3 3 14 
50-69 2 3 3 3 3 14 
70+ 2 1 2 1 1 7 
Highest level of education Year 10 3 1 2 0 0 6 
Year 12 or College 5 7 5 7 9 33 
Bachelor’s degree 
or higher 
2 2 3 3 1 11 
Main language spoken at 
home 
English 10 8 10 9 9 46 
Other 1
a
 2 3
a
 1 1 8 
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Demographic  Voltaren
®
  
Rapid 25  
cohort  
(n=10) 
‘Medicine 
Information’ 
cohort  
(n=10) 
‘Medicine 
Facts’ 
cohort 
(n=10) 
‘Consumer 
Desires’ 
cohort 
(n=10) 
‘Drug 
Facts’ 
cohort 
(n=10) 
Total 
(n=50) 
Regular use of written 
information as part of 
occupation 
Yes 3 8 5 4 7 27 
No 7 2 5 6 3 23 
Country of birth Australia 4 6 4 8 4 26 
Overseas 6 4 6 2 6 24 
a 
Participants also specified English as a main language spoken at home (language categories were not mutually exclusive, hence cohort total 339 
may exceed 10)    340 
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Table 3. Summary of the user testing findings for all 5 label formats 341 
 
User testing questionnaire (UTQ) item 
Voltaren®  
Rapid 25 
(n=10) 
‘Medicine 
Information’ 
(n=10) 
‘Medicine  
Facts’ 
(n= 10) 
‘Consumer 
Desires’  
(n=10) 
‘Drug  
Facts’ 
(n=10) 
Found  
(n, 
difficulty
a
) 
Under-
stood 
Found 
(n, 
difficulty) 
Under-
stood 
Found 
(n, 
difficulty) 
Under-
stood 
Found 
(n, 
difficulty) 
Under-
stood 
Found  
(n, 
difficulty) 
Under-
stood 
1. What is the active ingredient found 
in [insert diclofenac brand]? 
10 (0) 10 10 (0) 10 10 (0) 10 10 (0) 10 10 (0) 10 
2. You are taking [insert diclofenac 
brand] to relieve your back pain. 
How much should you take and how 
often? 
10 (0) 9 10 (0) 10 10 (0) 10 10 (0) 10 10 (0) 10 
3. Pretend that you are pregnant. 
After coming home from the 
pharmacy, you realize you did not 
tell the pharmacist that you are 
pregnant at the moment. What 
should you do? 
10 (0) 9 10 (0) 10 10 (0) 10 10 (0) 10 10 (0) 10 
4. How should you store these tablets?  10 (0) 10 10 (0) 10 10 (1) 10 10 (0) 10 10 (0) 10 
5. Pretend you have already taken SIX 
[insert diclofenac brand] tablets so 
far today for your pain. How many 
more tablets can you still take 
today? 
10 (0) 10 10 (1) 10 10 (0) 10 10 (0) 10 10 (0) 10 
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User testing questionnaire (UTQ) item 
Voltaren®  
Rapid 25 
(n=10) 
‘Medicine 
Information’ 
(n=10) 
‘Medicine  
Facts’ 
(n= 10) 
‘Consumer 
Desires’  
(n=10) 
‘Drug  
Facts’ 
(n=10) 
Found  
(n, 
difficulty
a
) 
Under-
stood 
Found 
(n, 
difficulty) 
Under-
stood 
Found 
(n, 
difficulty) 
Under-
stood 
Found 
(n, 
difficulty) 
Under-
stood 
Found  
(n, 
difficulty) 
Under-
stood 
6. Pretend your father has just bought 
some [insert diclofenac brand] from 
the pharmacy. He tells you that he 
forgot to tell the pharmacist that he 
has a stomach ulcer at the moment. 
What would you tell your father 
about taking [insert diclofenac 
brand]? 
10 (0) 10 10 (0) 10 10 (1) 10 10 (0) 10 10 (0) 10 
7. SHOW CARD:  
A picture of Nurofen® Cold and Flu 
tablets 
Active ingredient: Ibuprofen (NSAID 
anti-inflammatory) 
Pseudoephedrine (relieves blocked 
noses) 
Pretend you are currently taking 
[insert diclofenac brand] tablets and 
have just come down with a cold. 
You have some Nurofen® Cold and 
Flu tablets at home. What does the 
box say about taking this medicine 
together with [insert diclofenac 
brand]? 
10 (0) 10 10 (0) 10 10 (1) 10 10 (0) 10 10 (2) 10 
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User testing questionnaire (UTQ) item 
Voltaren®  
Rapid 25 
(n=10) 
‘Medicine 
Information’ 
(n=10) 
‘Medicine  
Facts’ 
(n= 10) 
‘Consumer 
Desires’  
(n=10) 
‘Drug  
Facts’ 
(n=10) 
Found  
(n, 
difficulty
a
) 
Under-
stood 
Found 
(n, 
difficulty) 
Under-
stood 
Found 
(n, 
difficulty) 
Under-
stood 
Found 
(n, 
difficulty) 
Under-
stood 
Found  
(n, 
difficulty) 
Under-
stood 
8. Imagine you know that your body 
reacts badly when you have sucrose. 
What does the box tell you about 
whether you can take this 
medicine? 
10 (1) 10 10 (0) 10 8 (1) 8 8 (2) 8 10 (1) 10 
9. What can [insert diclofenac brand] 
be used for? 
10 (0) 10 10 (0) 10 10 (0) 10 10 (0) 10 10 (0) 10 
10. Pretend you have been taking 
[insert diclofenac brand] for about 4 
days in a row now but the pain has 
not gone away or improved. What 
does the box say you should do? 
10 (5) 7 10 (2) 8 10 (4) 8 10 (3) 10 10 (3) 10 
11. If you wanted to know more about 
this medicine, who can you contact 
or where can you go? 
10 (1) 10 10 (0) 10 10 (0) 10 10 (0) 10 10 (0) 10 
12. What side effects should you look 
out for whilst taking [insert 
diclofenac brand]?  
n/a  
(not on 
label) 
n/a 10 (0) 10 10 (0) 10 10 (0) 10 10 (0) 10 
13. What is the longest amount of time 
that this medicine can be used for? 
9 (0) 9 10 (0) 10 10 (0) 10 10 (0) 10 10 (0) 10 
a
 The number of participants who had difficulty finding the information342 
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Table 4. Summary of other potential improvements suggested by participants who user tested the label format specifically 343 
Label  Design improvements Content improvements Wording improvements 
Voltaren® 
Rapid 25 
Re-ordering and/or relocation of information 
• Higher up: Directions for use, “Do not take” 
section 
• Move treatment duration to beginning of “Do 
not” section or together with action to be taken if 
symptoms persist 
• Group information requiring you to see the doctor 
together under “Precaution” e.g. allergic reaction, 
if symptoms persist 
Other 
• Include a separate box to state the ingredients 
• List and number dosage information 
Addition 
• How it will work; common side 
effects; type of medications it 
cannot be used with; specific 
treatment duration; other 
information sources; what 
liquid to take medication with 
Deletion 
• Some warnings; statements: 
use only as directed, do not 
exceed stated dose, see doctor 
regarding allergic reaction, 
prolonged use could be 
harmful; maximum daily dose 
Uses 
• Replace migraine with 
headache 
Directions for use  
• Dosing interval as 8 hours; 1 
day as 24 hours (maximum 
daily dose) 
Warnings and/or precautions 
• Clearer, concise pregnancy 
warning  
• “If symptoms persist, stop the 
medicine and see your 
doctor” 
Headings 
• “Warnings” instead of “Do 
not take”  
‘Medicine 
Information’ 
Re-ordering and/or relocation of information 
• Higher up: Directions for use 
• Lower down: Warnings, Ingredients, all contact 
information 
• Allergy information together with “Ingredients” 
Addition 
• All ingredients 
Deletion 
• Content repetition; 
sponsor/contact details  
 
Headings 
• Reword “Uses” 
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Label  Design improvements Content improvements Wording improvements 
‘Medicine 
Facts’ 
Re-ordering or relocation of information 
• Higher up: Directions for use, Warnings, Inactive 
ingredients (after Active ingredient) 
• Lower down: “Do not use”, Active ingredient, Uses 
• Combine action to be taken if symptoms persist 
and maximum treatment duration - include under 
“How to take” 
• Storage information above Poisons Information 
Centre 
• Sucrose to “Things to be careful of” 
• “Other information” on another panel 
Addition 
• When to take in relation to 
meals; sucrose on back panel; 
why sucrose is highlighted  
Deletion 
• Statement about reading leaflet 
(back panel); other information 
except website 
Warnings and/or precautions 
• Clearer statement of when to 
stop taking the medicine  
Headings 
• “Dosage” instead of “How to 
take”  
• “Filling up ingredients” 
instead of “Inactive 
ingredients” 
‘Consumer 
Desires’ 
Re-ordering or relocation of information 
• Higher up: Warnings  
• Lower down: Directions for use, Other 
information 
• Include maximum duration of use, if symptoms 
persist, and overdose information together under 
“What should I be careful of?” 
• Move “Other information” or “Ingredients” to side 
panel 
Other 
• White background 
• Ingredients listed in bullet points 
Deletion 
• Statement about reading leaflet 
(back panel); Uses (just state 
pain reliever); unnecessary 
words 
Headings 
• “Warnings” instead of “Do 
not use” 
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Label  Design improvements Content improvements Wording improvements 
‘Drug Facts’ Re-ordering or relocation of information 
• Higher up: Directions for use  
• Lower down: Warnings, Active ingredient, Other 
information 
• Side effects under “Warnings” 
• Move “When using this product” to another panel 
Other 
• More white background 
• Landscape orientation for back panel 
• Include maximum daily dose in a sentence 
together with dosage  
• Separate out adults and children and tabulate 
dosage 
Addition 
• Sucrose on back panel 
• Elaborate on “at first” (dosage) 
• Warning regarding driving or 
drinking alcohol whilst using 
this medicine 
Deletion 
• Common side effects 
Headings 
• “Inactive ingredients” instead 
of “Other ingredients” 
• “Main active ingredient” 
instead of just “Active 
ingredient” 
• “Side effects” as a heading 
When using this product 
• State not to use with other 
anti-inflammatories and 
diclofenac-containing 
medicines together 
• Advise to be aware of side 
effects 
Directions for use 
• Delete “at first” and rephrase 
dosage 
 344 
  345 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
Page 23 of 40 
 
Consumer perspectives on the label formats 346 
Overview- participant label rankings and preferences 347 
The ‘Consumer Desires’ label format scored highest (Table 5). In the label ranking 348 
exercise, it was cited most frequently as the most preferred OTC label format (n=17), 349 
followed closely by the ‘Drug Facts’ label (n=15). The ‘Medicine Information’ label was 350 
the label least often ranked 1
st
 (most preferred) by participants (n=4). 351 
The majority of participants were in support of OTC label standardization as a labeling 352 
strategy. Similar to the rankings, consumers most commonly chose the ‘Consumer 353 
Desires’ or ‘Drug Facts’ label formats as their favored standardized OTC label format 354 
for implementation. Conversely, the ‘Medicine Information’ label format was only 355 
nominated by a few participants. 356 
Consumer perspectives on the label formats varied considerably. Differences in factors 357 
such as perceived usability, visual appeal, use of colour, design, content amount/type, 358 
and/or order of information influenced consumer label preferences and subsequent 359 
rankings. The label-specific characteristics mentioned by consumers when comparing 360 
and ranking labels are the focus herein. 361 
 362 
Table 5. Tallied points for each label according to the nominated ranks per cohort 363 
  User testing participant cohorts   
  Voltaren® 
Rapid 25 
cohort 
(n=10) 
‘Medicine 
Information’ 
cohort 
(n=10) 
‘Medicine 
Facts’ 
cohort 
(n=10) 
‘Consumer 
Desires’ 
cohort 
(n=10) 
‘Drug 
Facts’ 
cohort 
(n=10) 
Total 
points 
per 
label 
format 
 
 
 
 
 
Label 
format  
 
Voltaren® 
Rapid 25 
label 
26 25 32 29 27 139 
‘Medicine 
Information’ 
label 
27 30 24 27 31 139 
‘Medicine 
Facts’ label 
29 32 33 29 31 154 
‘Consumer 
Desires’ 
label 
34 40 37 30 31 172 
‘Drug Facts’ 
label 
34 23 26 36 31 150 
 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
Page 24 of 40 
 
‘Consumer Desires’ label format 364 
The majority of participants who ranked the ‘Consumer Desires’ as their most 365 
preferred label (14/17) were aged 18-39 years. Participants liked its visual appeal. The 366 
use of color, in particular the contraindications’ section presented using red, was 367 
frequently mentioned as beneficial in highlighting the information, along with the tick 368 
cross pictograph system (utilized to help communicate the indications and 369 
contraindications information). Aspects that were liked about the ‘Consumer Desires’ 370 
label format included:  371 
• Directions for use situated higher up, along with its tabulation;  372 
• Both active and inactive ingredients being presented together; 373 
• Distinct sectioning of information within the main label;  374 
• Inclusion of all information on 1 main panel; and  375 
• Use of colloquial language. 376 
“The colored one immediately stands out to me because it’s got a panel which is red 377 
with some crosses which immediately says to me ‘Danger, danger. You need to read 378 
this.’ So umm, I think that’s, that’s quite good.” (P42- ‘Drug Facts’ cohort) 379 
“I’m really liking this colored one with the crosses and the ticks. Umm and I like the fact 380 
that each heading is contained within its own sort of graphically designed bubble, if 381 
you like. Umm, [it] makes the information really easy to find. It’s sort of like an index on 382 
the back of the box.” (P42- ‘Drug Facts’ cohort) 383 
Despite these positives, there were a number of shortcomings. Some participants 384 
thought that the ‘Consumer Desires’ label format was too busy; small print, excessive 385 
color, too much information, and minimal background space were negative 386 
characteristics raised. The question-style headings were also not favored.   387 
 388 
  389 
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‘Drug Facts’ label format 390 
The majority of participants who most preferred the ‘Drug Facts’ label format (12/15) 391 
were 40 years or older. Participants liked the clearer, simple layout, larger font, and 392 
the ease with which it could be read. The black print on white was seen to stand out; 393 
the use of space was also seen as good. The content was liked (e.g. specification that 394 
diclofenac is a NSAID) and the categorization and separation of information made 395 
information easy to find.  396 
Similar proportions of participants nominated the ‘Drug Facts’ label as the most 397 
preferred or least preferred label, which has contributed to its slightly lower total point 398 
score (Table 5). It was perceived as an unappealing, boring, or outdated design. 399 
Comparisons were made to nutrition labeling or cigarette packaging. Directions for use 400 
located at the bottom or information located on the side panel were generally not 401 
favored. Further still, separate areas of information did not stand out, for instance, 402 
when referring to the label format quickly. Participants also opposed the title “Drug 403 
Facts” as it “makes it sound like marijuana or something” (P30- ‘Medicine Information’ 404 
cohort). Participants expressed mixed feelings regarding the information, black bullet 405 
points, and the border. The two-column format also affected perceptions on how 406 
easily the label could be read.   407 
“That’s just a really bad packaging… Whoever designed that needs to probably go back 408 
to design school.” (P12- Voltaren® Rapid 25 cohort) 409 
“I think it’s a no no, just ‘cause it is very hard to read. It is all black and all. It’s not 410 
colour coded as this one is. So I don't think this is very helpful.”(P21- ‘Consumer Desires’ 411 
cohort) 412 
 413 
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‘Medicine Facts’ label format 415 
The ‘Medicine Facts’ was seen as very similar to the ‘Medicine Information’ label 416 
format. The navy blue print was seen as more attractive than black print. The layout 417 
was seen as easy to read, with good, clear, dark banded headings, some white space, 418 
bullet points, and sectioning.  419 
“It’s not an overly complicated box. Like, it’s not millions of things going on so that does 420 
make it a bit easier to use as well.” (P17- ‘Medicine Facts’ cohort) 421 
Differing opinions on the amount of information was evident; it was liked but on the 422 
other hand, also seen as too much. The order of information was commented on, 423 
where it did not always correspond with consumers’ preference or perceived 424 
importance of information. Furthermore, difficulty locating the dosage was reported; it 425 
“breaks up the warnings with ‘How to take Viffarol’ in the middle and I just feel like it’s 426 
really random that the directions are here. Like, it kind of gets lost in it.” (P02- 427 
‘Medicine Information’ cohort). Information included on the side panel was not liked, 428 
with participants believing that the information could be missed. Font size was disliked 429 
and the colour was also seen as not sharp enough. 430 
“I don’t know. It’s sort of too much. It’s all the same colour and it all blends down 431 
together. It’s harder to find. You can see it, obviously, but it’s harder to find.” (P37- 432 
‘Consumer Desires’ cohort) 433 
 434 
‘Medicine Information’ label format 435 
Participants liked the clear, banded headings, clear information, bullet points, and 436 
grouping of contraindications and precautions information together. The black print on 437 
white was easier to read for some than the navy blue print. Mixed opinions on font 438 
size appropriateness were seen.  439 
On the other hand, the monochrome design was viewed as unappealing and 440 
unengaging. Participants generally did not like the order of information; in particular, 441 
the inclusion of directions for use near the bottom of the label. The amount of 442 
information was also seen as too much.  443 
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Voltaren® Rapid 25 label format 444 
Participants liked the color (navy blue print), the order of information (specifically, that 445 
the directions for use were at the top of the label), font size, and the prominence of 446 
the storage information. The simple design, with only 3 headings utilized, and heading 447 
style were also liked.  448 
On the other hand, the Voltaren® Rapid 25 label was seen to be lacking in content. It 449 
was criticized for having lengthy individual dot points or sentences, deficient sectioning 450 
of information, and an extensive “Do not take”
18
 section.  451 
“It [is] a lot of things to read under one heading, so… I don’t find that easy to, you 452 
know, just go through.” (P14- ‘Medicine Facts’ cohort) 453 
 454 
General comments on label characteristics 455 
Consumers generally preferred short headings (although headings adopting a 456 
question-style or use of laymen terms were also liked on occasion). Overall, core 457 
information included on 1 main panel (where possible) was preferred. However, of 458 
those who preferred or were comfortable with splitting information across multiple 459 
panels, information that was less important, less useful, or less often used could be 460 
included on a side panel. Where some felt indifferent or did not see inactive ingredient 461 
information as useful (e.g. if it was not understood or in the absence of allergies), 462 
others felt that complete information should be provided on the label for the purposes 463 
of transparency or as a precaution.   464 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
Page 28 of 40 
 
Discussion 465 
 466 
To the best of the authors’ knowledge, this is the first study that has developed and 467 
tested, using industry-standard user testing, labels based on TGA consultation 468 
proposals, and more importantly, alternative ones based on good information design 469 
principles and a consumer needs analysis. All developed label formats demonstrated 470 
satisfactory usability in accordance with benchmark user testing standards
20
 and thus, 471 
could be considered as candidates for use as standardized OTC label formats. Their 472 
usability was also superior to the existing label for Voltaren® Rapid 25. Participants 473 
supported the standardization of OTC labeling, similar to previous studies.
14, 15
 474 
Specifically, the 2 labels most frequently preferred and nominated as the format of 475 
choice for standardization were the ‘Drug Facts’ and ‘Consumer Desires’ labels. 476 
The ‘Drug Facts’ label was the superior label of the 5 in terms of usability, with all 10 477 
participants finding and understanding all key points. This may be due to label aspects 478 
such as the larger font size and ample white space integrated into its layout in 479 
comparison to the other labels, where larger font has been previously associated with 480 
improved usability by consumers when answering questions about the information on 481 
an OTC label.
26, 27
 In particular, this may explain why all participants user testing the 482 
‘Drug Facts’ label identified that the product contained sucrose (for UTQ item 8), 483 
compared to the ‘Medicine Facts’ or ‘Consumer Desires’ label formats. On the other 484 
hand, on the Voltaren® Rapid 25 and ‘Medicine Information’ labels, only sucrose was 485 
specified as the sole additional ingredient rather than a complete list as seen in the 486 
other labels. This could explain why no issues pertaining to UTQ item 8 were detected 487 
when these labels were user tested. Overall, a few consumers in each cohort had 488 
difficulty finding the complete indicative answer for UTQ item 10 (actions to be taken 489 
in response to persistent pain). This was due to the relevant information being located 490 
in more than 1 label section. Thus, consolidating this information together in 1 section 491 
is a potential target for future label optimization. 492 
  493 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
Page 29 of 40 
 
Consumer preferences with respect to OTC labels can vary with differences exhibited 494 
in label characteristics, such as ordering of information
28
 and design aspects such as 495 
print size and spacing,
29
 which were also aspects commented on by the study 496 
participants. However, with respect to the ‘Drug Facts’ and ‘Consumer Desires’ labels, 497 
participant feedback received in the present study suggest a degree of consistency in 498 
specific label characteristics favored by consumers- for example, the suggested use of 499 
red to convey warnings
14
 and support for the ‘Drug Facts’ label
15
 as identified in the 500 
initial consumer needs analysis. Furthermore, suggested improvements mirrored some 501 
received in the consumer needs analysis, especially if the label format they user tested 502 
did not display these characteristics e.g. further use of bolding and color, inclusion of 503 
directions for use higher up, and active ingredient lower down in the label.
14
 This order 504 
of information and use of red to highlight the contraindications were all characteristics 505 
of the ‘Consumer Desires’ label. On the contrary, the ‘Medicine Information’, the 506 
Australian TGA format proposed in 2014,
12
 achieved the lowest total point score and 507 
was nominated least often as the chosen standardized format to be implemented. 508 
When considering usability in tandem with consumer preferences and feedback given 509 
as part of the present study, a hybrid of the ‘Consumer Desires’ and ‘Drug Facts’ labels 510 
could be considered for use as an OTC standardized label format for implementation 511 
by countries seeking to adopt a label standardization strategy. Aspects of each label 512 
could address the perceived shortcomings of the other across different demographics 513 
(as these 2 labels were the most different from each other). For instance, in terms of 514 
specific characteristics, the ‘Drug Facts’ label could be amended to reflect the order of 515 
information on the ‘Consumer Desires’ label; other aspects such as the moderate use 516 
of color (e.g. the red used for warnings information was liked) and use of the tick cross 517 
pictograph system could also improve its visual appeal. The larger font size and ample 518 
white space should also be retained as these are aspects of good information design.
4
  519 
  520 
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With regards to standardization as a labeling strategy, a one-size-fits-all approach will 521 
inherently have its limitations in its ability to satisfactorily cater for the needs of the 522 
entire consumer population. Consumer preference may not always equate to a label 523 
that actually performs well, as was evident in the diversity of participant perspectives 524 
on the 5 study label formats. For instance, user testing demonstrated that the active 525 
ingredient could still be found even if not presented initially at the top of the label. 526 
Thus, the present study does not provide evidentiary support of an advantage in 527 
including the ingredients foremost, particularly when consumers generally do not 528 
prefer this approach, as voiced in both the present and previous
8, 14, 28
 studies. 529 
Importantly, usability must remain the focal point for improvement of OTC labeling 530 
quality as OTC label information may not be adequately understood and can be 531 
inappropriately acted upon.
30-32
 It is imperative to consult consumers in the written 532 
medicine information development process as by doing so, targets for improvement of 533 
OTC medicine information can be identified.
33-36
 Interestingly, Bix et al.
37
 534 
demonstrated that adherence to labeling requirements embedded in standardized 535 
labeling regulations, such as those stipulated for the Drug Facts label, may still yield 536 
variations in the legibility of label formats. In addition, a recent study conducted in the 537 
U.S. by Bhansali et al.
38
 noted that almost 80% of participants most preferred an 538 
alternative label format that included directions near the top of the label and warnings 539 
information lower down. In comparison, only approximately 14% most preferred the 540 
Drug Facts label format i.e. the order of information.
38
 Since requirements for 541 
standardized tabulation of information on OTC labels have now been formally 542 
published in both Australia and Canada (after the present study had been 543 
concluded),
39, 40
 this reinforces that ongoing research is important and necessary to 544 
ensure that standardization promotes the development of improved OTC labels for 545 
consumers. With standardized labeling, there is a risk of implementing a policy 546 
centered on an OTC label format that is not preferred by consumers, for whom the 547 
benefits are intended, or that would not yield optimal usability. Considering that all 548 
evidence-based label formats for the same exemplar medicine in the present study 549 
demonstrated comparable usability on the whole, this also brings into question the 550 
overall advantage of implementing a standardized label format in terms of usability. 551 
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At present, user testing of OTC medicine information is not required by law in Australia 552 
and is not routinely used to evaluate written medicine information.
41
 As legislation 553 
places emphasis on the content required for inclusion on labels,
42
 usability of existing 554 
OTC labels in regulatory contexts such as Australia remains largely unknown. Thus, 555 
future research on the impact of these labeling changes is critical and should feed into 556 
an iterative, consumer-centric user testing process for label optimization, as embodied 557 
in previous OTC label user testing studies.
34, 35
 Moreover, there are no legislated 558 
requirements in the U.S. for the user testing of all OTC labels; instead, guidelines are 559 
available which describe how testing of OTC labels can be conducted.
43
 This lack of 560 
mandated user testing may have implications on the quality of standardized OTC 561 
labels. Accordingly, a move towards legislating user testing may allow for more 562 
innovative labeling strategies that demonstrate superior usability to a standardized 563 
format. This may also more effectively take into account both consumer and 564 
manufacturer perspectives on OTC labeling.  565 
 566 
Study limitations 567 
This study has some limitations. It is acknowledged that the involvement of other 568 
experts, for instance, in the area of functional linguistics, would be useful to assist in 569 
label development. The options for label design are effectively unlimited in many 570 
ways, depending on how written medicine information developers opt to manipulate 571 
different parameters. Accordingly, in the present study, there was a pragmatic 572 
limitation on the number of label designs included for user testing which meant that 573 
not all possible label formats and combinations could be explored. In light of this, a 574 
range of different label characteristics was integrated across the different label 575 
formats. Also, the same packaging dimensions were used for all the developed label 576 
formats for consistency as they were developed for the same fictitious branded 577 
product. Thus, findings may differ if packaging size was altered. Optimal product-578 
specific labeling that meets the relevant requirements for standardization should also 579 
be evaluated by other key stake-holders in addition to consumers, such as 580 
pharmaceutical manufacturers. However, it is imperative to ensure that compromises 581 
are not made to the labels that will have an adverse impact on medication safety. 582 
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Conclusions 583 
 584 
All alternative OTC label formats developed and user tested in this study were 585 
effective in communicating key information overall and demonstrated better usability 586 
than the existing Voltaren® Rapid 25 comparator label format. This then highlights the 587 
effectiveness of implementing good information design principles in OTC label 588 
development and the need to improve existing OTC labeling. The satisfactory usability 589 
of these labels also emphasizes that consumer preferences can be utilised to help 590 
guide label development without compromising OTC label usability. Differences in 591 
factors such as design, content, and wording impacted both participants’ actual and 592 
perceived usability of the OTC label formats.  593 
As the TGA proposed ‘Medicine Information’ label format was least often nominated 594 
by participants as their preferred standardized OTC label format for implementation, 595 
this reinforces the importance of consulting consumers as key stakeholders in working 596 
towards the implementation of regulatory changes such as OTC label standardization. 597 
Aspects of the ‘Consumer Desires’ and ‘Drug Facts’ labels can be taken forward in 598 
refining the design of a standardized OTC label format that could be adopted in future, 599 
in line with both consumer preferences and usability testing data. In light of the recent 600 
introduction of new OTC medicine labeling policies that facilitate standardization in 601 
Australia, this study provides evidence in support of the advantages for adoption of a 602 
mandate for user testing to also be integrated into OTC labeling frameworks in future 603 
to evaluate and ensure label usability.  604 
 605 
  606 
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Figure captions 743 
 744 
Figure 1. ‘Medicine Information’ label format 745 
Figure 2. ‘Drug Facts’ label format 746 
Figure 3. ‘Medicine Facts’ label format 747 
Figure 4. ‘Consumer Desires’ label format 748 
Figure 5. Complete “Viffarol” packaging for the ‘Medicine Information’ label format 749 
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Appendix 753 
 754 
Appendix 1. Semi-structured interview protocol questions 755 
Semi-structured 
interview 
protocol sections 
Questions 
Perspectives on 
the user tested 
label 
• Firstly, what are your overall thoughts about the box that you 
just helped us test, in terms of how easy/hard it is to read and 
the information that is included on it? 
• Looking at the information on the box, what do you think 
about the amount of information that it contains? 
• What do you think about the layout of the information on the 
box? 
• Thinking back to how you used the box to answer the 
questions before, what information was easy or difficult to 
find and/or understand? 
• From your point of view, how can we improve the box in the 
future to improve its readability and how well it is 
understood? 
Perspectives on 
all other label 
formats 
• Firstly, what are your overall thoughts about these boxes, in 
terms of how easy/hard it is to read and the information that 
is included on it? 
• What do you think about the amount of information that each 
of these boxes contain? 
• What do you think about the layout of the information on the 
boxes? 
• What do you think about the headings used on these boxes? 
• What do you think about how the information is ordered on 
these boxes? 
• What do you think about how colour has been used on these 
boxes? 
• What do you think can be improved with these boxes to make 
them better in the future? 
Label format 
rankings 
• How would you rank all the boxes, from the one you most 
preferred to the least preferred? 
• Why did you rank them in this way? 
Standardization- 
preferred label 
format 
• If we had to choose a standard back of the pack for all over-
the-counter medicines, which would you choose out of the 5 
and why? 
• How would you feel if this was the one we rolled out onto all 
over-the-counter medicines in Australia? 
• Taking a step back from the boxes in front of you, what do 
you think about having standardised back of the packs/boxes 
for all over-the-counter medicines?  
 756 
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Developing alternative over-the-counter medicine label formats: how do 
they compare when evaluated by consumers? 
Highlights 
• Four alternative label formats for diclofenac were developed with consumer input in 
response to proposed changes to Australian over-the-counter (OTC) medicine labeling 
legislation. 
• All label formats demonstrated good usability, superior to that for an existing OTC diclofenac 
label. 
• Consumers expressed diverse opinions on the label formats’ design and content.  
• The proposed Therapeutic Goods Administration’s (TGA) standardized label format was only 
“most preferred” by 4 out of 50 consumers in total.  
• Both user testing data and consumer perspectives reinforced the need to optimize the TGA 
proposed standardized label format. 
